Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.22.1
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Mar. 31, 2022
Jun. 30, 2021
Current assets    
Cash and cash equivalents $ 8,839 $ 10,537
Prepaid expenses, deposits and other 1,254 756
Clinical trial deposit   500
Total current assets 10,093 11,793
Clinical trial deposit 2,600 1,600
Property, equipment and intangibles, net 105 150
Total assets 12,798 13,543
Current liabilities    
Accounts payable and accrued liabilities 2,782 2,219
Related party payables 458 561
Total current liabilities 3,240 2,780
Milestone payment liability 172 182
Total liabilities 3,412 2,962
Stockholders' equity    
Common stock Authorized 175,000 shares at March 31, 2022 and June 30, 2021, $0.001 par value 49,306 issued at March 31, 2022 (June 30, 2021 - 32,740) 49 33
Additional paid-in capital 127,670 106,821
Accumulated deficit (130,908) (111,225)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 9,386 10,581
Total liabilities and stockholders’ equity 12,798 13,543
Preferred Stock Series A    
Stockholders' equity    
Preferred stock 279 279
Preferred Stock Series C    
Stockholders' equity    
Preferred stock $ 12,275 $ 14,652